Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL22 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BL22 immunotoxin |
| Name | Type | Description |
|---|---|---|
| BL22 | DRUG | Dosing via IV on Days 1,3, and 5. |
DISEASE CHARACTERISTICS: * Histologically confirmed hairy cell leukemia * CD22-positive disease by fluorescence-activated cell sorting with anti-CD22 antibody * Meets at least 1 of the following indications for treatment: * Absolute neutrophil count less than 1,000/mm\^3 * Hemoglobin less than...
Top 20 of 60 competitors
BL22 is an investigational therapy being studied for the treatment of leukemia, specifically hairy cell leukemia in patients who have previously been treated with cladribine. It is a small molecule developed by AstraZeneca PLC and has completed a Phase 2 clinical trial.
BL22 targets CD22, a protein found on the surface of certain B cells. As a binding agent, it is designed to bind to CD22 and deliver a therapeutic payload to CD22-expressing cells, which is relevant in B-cell malignancies such as hairy cell leukemia.
BL22 is being developed by AstraZeneca PLC, a pharmaceutical company traded on the Nasdaq under the ticker symbol AZN. AstraZeneca is responsible for the clinical development of BL22.
BL22 is in Phase 2 clinical development. It has completed one Phase 2 trial and is not currently listed as having any active trials. BL22 is investigational and has not been approved by the FDA for any indication.
BL22 has been evaluated in a completed Phase 2 trial, NCT00074048, titled "BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia." The trial enrolled 36 patients in the United States and was an uncontrolled study.